Expert Strategies for Identifying Eligible Patients With DLBCL and FL for CAR T-Cell Therapy
Webinar/Online
Thursday, October 16, 2025 at 2:00pm ET - 2:30pm ET
Add this event to your calendar
Info
Topic
Discover CAR T-cell and non-Hodgkin lymphoma (NHL) expert-driven strategies to enhance patient selection in our upcoming live webinar where faculty will provide actionable insights on recognizing clinical indicators and navigating eligibility criteria to identify appropriate candidates for CAR T-cell therapy in diffuse large B-cell lymphoma (DLBCL) and follicular lymphoma (FL). Leveraging key insights stemming from recent surveys and CAR T clinical connection sessions and the introduction of a customizable Referral Ready blueprint, expert faculty will present the latest evidence and guideline recommendations to ensure your patients receive timely, potentially life-changing treatment.
Credits Offered
This event offers
0.5 contact hours
to attendees.
Accreditation Info:
AANP.
Additional Information
From recent surveys and CAR T clinical connection sessions, expert faculty will present the latest evidence and guideline recommendations to ensure your patients receive timely, potentially life-changing treatment.
Speakers
Director, Lymphoma Program
Medical Director, Lean and Quality Improvement
Associate Professor
Division of Hematologic Malignancies and Cellular Therapeutics
University of Kansas Cancer Center
Kansas City, KS
Medical Director, Immune Effector Cell Therapy Program
Dana Farber Cancer Institute
Associate Professor of Medicine
Harvard Medical School
Boston, MA